Yesintek, formerly known as Bmab 1200, is a human interleukin-12 and -23 antagonist. The FDA has approved Yesintek (Ustekinumab-kfce), a biosimilar to Stelara (Ustekinumab), for the treatment of ...

The approval marks the sixth biosimilar to reference Stelara (ustekinumab), and it will be used to treat several immunology ...

Results of a Phase III study conducted by an international team of researchers reveal that mirikizumab is more effective and ...

YESINKTEK is the sixth ustekinumab biosimilar approved by the FDA, behind Amgen’s WEZLANA (ustekinumab-auub), approved in Oct. 2023; Alvotech’s SELARSDI (ustekinumab-aekn), approved in April 2024; ...

The approval of Yesintek (ustekinumab-kfce), the sixth biosimilar to reference Stelara, will be used to treat patients with ...

Planegg-Martinsried, Germany / Amman, Jodan – Formycon AG (FSE: FYB, Prime Standard) and MS Pharma jointly announce that they have entered into a licensing and supply agreement for the ...

Germany’s Formycon has entered into a licensing and supply agreement with MS Pharma for the commercialization of FYB202, ...

After filing a new drug submission for its ustekinumab biosimilar PYZCHIVA (Janssen’s STELARA), Samsung commenced the ...

A key provision of the Inflation Reduction Act (IRA) of 2022 directed Medicare to negotiate the prices of certain top-selling ...

Mean duration of Crohn's disease was 7.4 years. Nearly half (48.5%) had previous biologic therapy failure, 45.7% had previous ...

Bangalore: Biocon has sold Eighty Lacs equity shares of Syngene International Limited for Rs. 686 crores. The transacted ...

The US Food and Drug Administration (FDA) has approved ustekinumab -kfce (Yesintek) as a biosimilar to ustekinumab (Stelara) for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis, ...